Point-of-care time-resolved immunofluorometric assay for human pregnancy-associated plasma protein A: Use in first-trimester screening for Down syndrome

Clinical Chemistry

Volumn 48, Issue 3, 2002, Pages 473-483

  Qin, Qiu Ping ^a   Christiansen, Michael ^a   Pettersson, Kim ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATE; CHORIONIC GONADOTROPIN BETA SUBUNIT; EUROPIUM; LANTHANIDE; LYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10E1; MONOCLONAL ANTIBODY 234 5; PREGNANCY ASSOCIATED PLASMA PROTEIN A; REAGENT; STREPTAVIDIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; BIOTINYLATION; BLOOD ANALYSIS; CALIBRATION; CHELATION; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DOWN SYNDROME; EARLY DIAGNOSIS; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; FLUOROMETRY; GENETIC SCREENING; GONADOTROPIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MATERNAL PLASMA; POINT OF CARE TIME RESOLVED IMMUNOFLUOROMETRIC ASSAY; PRENATAL DIAGNOSIS; PROTEIN DETERMINATION; PROTEIN STABILITY; SERUM; STATISTICAL ANALYSIS; TIME;

EID: 0036181025     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.3.473     Document Type: Article

References (49)

1. Characterization of four human pregnancy-associated plasma proteins
2. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein
3. Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor
4. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A
5. Evidence that the interaction between insulin-like growth factor (IGF)-II and IGF binding protein (IGFBP)-4 is essential for the action of the IGF-II-dependent IGFBP-4 protease
6. Pregnancy-associated plasma protein-A (PAPP-A) cleaves insulin-like growth factor binding protein (IGFBP)-5 independent of IGF: Implications for the mechanism of IGFBP-4 proteolysis by PAPP-A
7. Localization of pregnancy-associated plasma protein-A and colocalization of pregnancy-associated plasma protein-A messenger ribonucleic acid and eosinophil granule major basic protein, messenger ribonucleic acid in placenta
8. Evidence that the insulin-like growth factor binding protein-4 protease in human ovarian follicular fluid is pregnancy associated plasma protein-A
9. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty
10. Pregnancy-associated plasma protein A in the prediction of early pregnancy failure
11. Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability?
12. Serum PAPP-A and free β-hCG are first-trimester screening markers for Down syndrome
13. First trimester biochemical screening for trisomy 21: The role of free β hCG, α fetoprotein and pregnancy associated plasma protein A
14. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy
15. Time-resolved immunofluorometric assay of pregnancy-associated plasma protein A in maternal serum screening for Down's syndrome in first trimester of pregnancy
16. Screening of maternal serum for fetal Down's syndrome in the first trimester
17. Down syndrome and other autosomal trisomies
18. Four-marker serum screening for Down's syndrome
19. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency
20. First-trimester screening for Down syndrome using nuchal translucency measurement with free β-hCG and PAPP-A between 10 and 13 weeks of pregnancy - The combined test
21. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency
22. One stop clinic for assessment of risk for fetal anomalies: A report of the first year of prospective screening for chromosomal anomalies in the first trimester
23. Second trimester abortions: Trends and medical complications
24. Double-monoclonal immunofluorometric assays for pregnancy-associated plasma protein A/proeosinophil major basic protein (PAPP-A/proMBP)complex in first-trimester maternal serum screening for Down Syndrome
25. Dual-label time-resolved immunofluorometric assay for simultaneous determination of pregnancy-associated plasma protein A and free β-subunit of human chorionic gonadotrophin
26. Maternal serum screening for Down syndrome in the first trimester: Experience from Belarus
27. First-trimester biochemical markers for Down syndrome
28. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland
29. One-step all-in-one dry reagent immunoassays with fluorescent europium chelate label and time-resolved fluorometry
30. Ultrasensitive two-site immunometric assay of human lutropin by time-resolved fluorometry
31. Time-resolved fluorometry (TRF)-based immunoassay concept for rapid and quantitative determination of biochemical myocardial infarction markers from whole blood, serum and plasma
32. Influence of specimen carryover on sensitive thyrotropin (TSH) assays: Is there a problem?
33. First-trimester screening for fetal anomalies with nuchal translucency
34. Precision of risk in multidimensional likelihood ratio based screening with first trimester screening for Down's syndrome as a special case
35. First trimester screening for Down syndrome and assisted reproduction: No basis for concern
36. Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma
37. A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): A possible first trimester method of screening for Down syndrome and other trisomies
38. Antiserum to pregnancy-associated plasma protein A (PAPP-A) recognizes human haptoglobin
39. Pregnancy associated plasma protein-A: Interaction with heparin in crossed affinity immunoelectrophoresis
40. Effect of anticoagulants on the measurement of pregnancy-associated plasma protein-A (PAPP-A)
41. Specific and reversible interaction between pregnancy-associated plasma protein A and heparin
42. The development and validation of a RIA for human pregnancy-associated plasma protein A (PAPP-A)
43. Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA
44. Mutational analysis of the proteolytic domain of pregnancy-associated plasma protein-A (PAPP-A): Classification as a metzincin
45. Pregnancy-associated plasma protein A (PAPP-A): Measurement by highly sensitive and specific enzyme immunoassay, importance of first-trimester serum determinations, and stability studies
46. Time-resolved fluoroimmunoassay, advantages and limitations
47. Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: Implications for point-of-care testing
48. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes